SARS Vaccine Achieves Neutralizing Responses in First U.S. H... (id Vijay Samant Vical's Presidentand Chi...)

SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial

Date:12/9/2008

id Vijay Samant, Vical's President and Chief Executive Officer. "With the data from this successful Phase I trial and control of the IND, we are prepared to advance this vaccine quickly in the event of another outbreak. In the meantime, we can look to the model established with this program in addressing other emerging infectious diseases."

Side effects in the Phase I trial were typically mild, and no serious adverse events were reported. SARS-specific neutralizing antibody responses were detected in 8 of 10 subjects. SARS-specific CD4+ T-cell responses were detected in all 10 subjects, and CD8+ T-cell responses were detected in 2 of 10 subjects. Neutralizing antibody responses are important in preventing infection. CD4+ T cells help direct the appropriate immune resources against specific pathogens. CD8+ T cells find and kill infected cells and are important in clearing virus after infection.

About SARS

Following the initial cases of SARS, identified in the Guangdong Province of China in late 2002, the disease spread rapidly through the summer of 2003 and reached epidemic status, affecting more than 8,000 and killed more than 900 people in 25 countries before it was contained. SARS affects the respiratory system and gastrointestinal tract as well as other internal organs, with particular risk to the elderly and immunocompromised. Healthy adults may become infected and spread the disease without exhibiting any symptoms.

About DNA Vaccines

DNA vaccines may offer both technical and economic advantages compared with conventional vaccine approaches. DNA vaccines encode certain proteins associated with a target pathogen, rather than using any part of the pathogen itself, and can prime the immune system as well as induce antibody and T-cell immune responses. DNA vaccines contain no viral particles, are non-infectious, and can be administered on a repeat basis without unwanted imm
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa
2. Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
3. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
4. The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Countrys Biological Preparedness
5. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
6. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
7. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
8. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
9. U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vicals Vaxfectin(R) Adjuvant
10. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
11. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress

Post Your Comments:

(Date:12/16/2009)... 16 Today, Avantium announced the,appointment ... of its pharmaceutical,business. Gunnar Staaf previously worked ... Lilly & Company, in a range of ... important step in Avantium,s plan to,spin-out its ... a,stand-alone pharmaceutical company based on its offering ...

(Date:12/16/2009)... Lower Prescription Drug Prices ,, CHICAGO, Dec. ... night rejected an amendment to the Patient Protection ... prescription drugs more affordable by allowing for the ... from abroad. The bipartisan amendment, endorsed by ... Grassley and Stabenow, would have improved competition and ...

(Date:12/16/2009)... Dec. 16 Frost & Sullivan,s ... looks forward to speaking at the 2010 ... place on January 9, 2010 in Las ... emerging market of consumer-based digital health and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, Bujnoch focuses ...

Breaking Medicine Technology:Avantium Appoints Gunnar Staaf as CEO Pharma 2 AARP Illinois Key Vote News Alert 2 Frost & Sullivan to Speak at 2010 International Consumer Electronics Digital Health Summit 2 FDA Approves Lysteda to Treat Heavy Menstrual Bleeding 6264 1 FDA Approves Lysteda to Treat Heavy Menstrual Bleeding 6264 2 Facial Structure May Hold Clues to Aggression 61341 1 Donna H Ryan M D Elected President of The Obesity Society for 2009 2010 61336 1 Donna H Ryan M D Elected President of The Obesity Society for 2009 2010 61336 2 Donna H Ryan M D Elected President of The Obesity Society for 2009 2010 61336 3

[0] Avantium Appoints Gunnar Staaf as CEO Pharma [0] AARP Illinois Key Vote News Alert [0] Frost & Sullivan to Speak at 2010 International Consumer Electronics Digital Health Summit

... ASCO MeetingINDIANAPOLIS, May 30 Semafore Pharmaceuticals, Inc., ... company, today presented data from a Phase I ... SF1126, at the 2009 American Society of Clinical ... Florida.Dr. E. Gabriela Chiorean, from the Indiana ...

... 29 The American Society of Clinical ... research conducted at the Barbara Ann Karmanos ... ASCO,s Web site. Karmanos, potentially ground-breaking findings ... aggressive hormone receptor negative breast cancer tumors.(Logo: ...

Other Medicine Technology:Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients 2 Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients 3 Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy 2 Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy 3

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy

(Date:12/16/2009)... has been found, , , WEDNESDAY, Dec. 16 (HealthDay News) ... to food poisoning and the stomach pain and diarrhea ... some urinary tract infections. , Researchers have found the ... and restaurants and in women with the infections. ... directly to the women through the food they ate, ...

(Date:12/16/2009)... Age should not be determining factor for use, expert ... people with heart failure are much less likely to ... a new study. , The study included 4,685 people, ... device and had a left ventricular fraction (a measure ... less. , During a three-year period, those who were ...

(Date:12/16/2009)... OrthoAccel Technologies, Inc., developers of the ... device to enhance orthodontics, announced Alison Davies as ... Ms. Davies has spent the last fourteen ... industry, most recently for nine years as a ... of Invisalign . ,, (Logo: ...

(Date:12/16/2009)... Retirement Services Division has announced plans to introduce ... 2010. The new platform will include a full ... in a variety of themes. Plan sponsors will ... of creative options to support the theme best ... RetireSmart participant engagement platform will be phased in ...

(Date:12/16/2009)... diagnostic procedures in cardiology. The idea of publishing an ... of European cardiovascular imagers, is therefore long awaited. The ... with a patient rather than technology-based approach, helping clinicians ... aid of imaging. , The book is divided ... practice of cardiac imaging and its clinical use in ...

Breaking Medicine News(10 mins):Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 2 Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 3 Health News:Implanted Defibrillator Might Extend Life 2 Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 2 Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 3 Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 4 Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 2 Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 3 Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 4 Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 5 Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 2 Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 3

[0] Foodborne E. Coli Suspected in Urinary Tract Infections [0] Implanted Defibrillator Might Extend Life [0] Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom [0] MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform [0] The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center

... earnings per share of $0.89, up 24%- Total revenues ... of $273 million, up 73%- 2009 EPS outlook increased ... Quest Diagnostics Incorporated (NYSE: DGX ), the ... announced that for the first quarter ended March 31, ...

... enhanced RadarFind RTLS , ... Morrisville, NC (PRWEB) April ... healthcare system in North Carolina,s Triangle region, has launched the ... Hospital location. After serving as a development partner since April 2008, ...

... Company Delivers Solid Financial Performance, Continues to Advance ... Corporation (NYSE: SGP ) today reported ... powered through to deliver a solid performance in ... CEO. "We overcame difficult currency comparisons and ...

... pharmaceutical companies find, evaluate and manage drug partners ... drug development lifecycleSAN FRANCISCO, April 21 ... partnering site for the pharmaceutical development and drug ... website, goBalto.com. goBalto transforms the way drug-development partners ...

... DEL MAR, Calif., April 21 Patient Safety Week ... automated blood pressure device (1979), the pulse oximeter (1983) ... personal financial profit. All of these technological devices clearly ... Dr. Barry Friedberg as a forward thinking, caring physician."Until ...

... Surgeons study indicating that 98% of breast cancer patients are satisfied ... surgeon , Dr. Bob Basu explains why breast reconstruction following a ... ... Houston TX (Vocus) April 21, 2009 -- The American Society ...

Quest Diagnostics Reports Strong Earnings Growth In First Quarter 2009 WakeMed Shares Best Practices for Tracking Assets, Patients Schering-Plough Reports Financial Results for 2009 First Quarter Contract Drug Development Resource, goBalto, Launches New Web-Based Platform, goBalto.com American Society of Anesthesiologists Recent Public Debate Comes to Dead End Houston Plastic Surgeon Cites ‘Therapeutic' Benefits for Women that Choose Breast Reconstruction After Mastectomy

... Novus Spectra photocoagulator delivers power and ... solid-state (DPSS) technology. Diode side-pumping technology ... the compact Novus Spectra system, and ... beam output and system reliability from ...

Features soft, low friction sheath that extends beyond the tip....

Designed to retain the desired curve during oral intubation....

Facilitates intubation of tracheal tubes....

Medicine Products:

Novus Spectra Photocoagulator SHERIDAN SOFT-TIP® 10Fr Intubating Stylet SHERIDAN SHER-I-SLIP® 10Fr Intubating Stylet Satin-Slip® 6FR Intubating Stylet

SARS Vaccine Achieves Neutralizing Responses in First U.S. H...(id Vijay Samant Vical's Presidentand Chi...),Health